JP6807423B2 - ガロカテキンの使用 - Google Patents
ガロカテキンの使用 Download PDFInfo
- Publication number
- JP6807423B2 JP6807423B2 JP2019053867A JP2019053867A JP6807423B2 JP 6807423 B2 JP6807423 B2 JP 6807423B2 JP 2019053867 A JP2019053867 A JP 2019053867A JP 2019053867 A JP2019053867 A JP 2019053867A JP 6807423 B2 JP6807423 B2 JP 6807423B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- control
- compound
- formula
- melatonin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 claims description 46
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 39
- 229960003987 melatonin Drugs 0.000 claims description 39
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 34
- 230000001965 increasing effect Effects 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 23
- 238000003786 synthesis reaction Methods 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 16
- 230000028327 secretion Effects 0.000 claims description 14
- 230000007958 sleep Effects 0.000 claims description 12
- 208000019116 sleep disease Diseases 0.000 claims description 12
- 101150028660 ASMTL gene Proteins 0.000 claims description 11
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 10
- 206010022437 insomnia Diseases 0.000 claims description 10
- 230000002439 hemostatic effect Effects 0.000 claims description 9
- 230000036651 mood Effects 0.000 claims description 9
- 101150071927 AANAT gene Proteins 0.000 claims description 8
- 235000021407 appetite control Nutrition 0.000 claims description 8
- 238000010253 intravenous injection Methods 0.000 claims description 7
- 238000010254 subcutaneous injection Methods 0.000 claims description 7
- 239000007929 subcutaneous injection Substances 0.000 claims description 6
- 230000006806 disease prevention Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000020685 sleep-wake disease Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 description 22
- 235000015872 dietary supplement Nutrition 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 101150058700 Tph1 gene Proteins 0.000 description 11
- 101150102279 ddc gene Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 235000013402 health food Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000035790 physiological processes and functions Effects 0.000 description 7
- 102100030547 Serotonin N-acetyltransferase Human genes 0.000 description 6
- 206010047139 Vasoconstriction Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 229940076279 serotonin Drugs 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000025033 vasoconstriction Effects 0.000 description 6
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 5
- 101000652292 Homo sapiens Serotonin N-acetyltransferase Proteins 0.000 description 5
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 description 5
- 101710111485 N-acetylserotonin O-methyltransferase-like protein Proteins 0.000 description 5
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 5
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 210000004560 pineal gland Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- -1 aromatic amino acid Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000013403 specialized food Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 108010074515 Arylalkylamine N-Acetyltransferase Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000024659 Hemostatic disease Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- MVAWJSIDNICKHF-UHFFFAOYSA-N N-acetylserotonin Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CNC2=C1 MVAWJSIDNICKHF-UHFFFAOYSA-N 0.000 description 1
- 102100027445 N-acetylserotonin O-methyltransferase-like protein Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000000793 pinealocyte Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000000053 special nutrition Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000016776 visual perception Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明はまた、神経代謝障害に関連する疾患の治療、神経代謝障害に関連する疾患の予防、食欲制御、気分制御、血管収縮制御、止血機能制御、および/または免疫応答制御における、式(I)の化合物の使用に関する。本発明はまた、TPH1遺伝子発現の増加、DDC遺伝子発現の増加、AANAT遺伝子発現の増加、および/またはASMTL遺伝子発現の増加における、式(I)の化合物の使用に関する。
本出願は、2018年9月19日に台湾経済部知的財産局へ出願された台湾特許出願第107133010号の優先権を主張するものであり、その開示は、参照によりその全体が本明細書に組み込まれる。
好ましくは、医薬組成物は、経口投与、経皮投与、静脈内注射、または皮下注射の形態で提供される。好ましくは、医薬組成物は、不眠治療用である。
好ましくは、本発明の方法は、不眠の治療、睡眠障害の改善、および睡眠制御のためのものである。本発明による方法において、式(I)の化合物を上述の医薬組成物として投与することができる。
したがって、本発明は、睡眠障害改善、食欲制御、睡眠制御、気分制御、血管収縮制御、止血機能制御、および/または免疫応答制御において式(I)の化合物を使用すること、医薬組成物の製造において式(I)の化合物を使用すること、ならびに有効量の式(I)の化合物を必要とする対象に投与する方法を提供することを含む、式(I)の化合物の使用に関する。本発明に従って提供される医薬組成物および方法はまた、TPH1遺伝子、DDC遺伝子、AANAT遺伝子、および/またはASMTL遺伝子の発現を増加させるためのものでもある。
1.本発明の式(I)の化合物:ChemFaces社(Rainbow Biotechnology CO., LTD)より購入、製品番号:CFN99137、CAS番号:3371−27−5。
2.SHSY5Y細胞:ATCCより購入、製品番号:CRL−2266。
3.DMEM培地:90%DMEM、10%FBS、および1%ペニシリン/ストレプトマイシン含有;DMEMはGibcoより購入(製品番号:12100−046)、FBSはGibcoより購入(製品番号:10437−028)、およびペニシリン/ストレプトマイシンはGibcoより購入。
4.RNA抽出キット:Geneaidより購入。
5.逆転写酵素(SuperScript(登録商標)III逆転写酵素):Invitrogen社より購入。
6.KAPA SYBR FAST qPCRキット:KAPA Biosystems社より購入。
7.Step One Plusシステム:ABI社より購入。
1.対照群:DMEM培地;
2.実験群:対照群と同様の培地に、0.0625μg/mlの式(I)の化合物を加えたもの。
Claims (7)
- メラトニン合成の増加、メラトニン分泌の促進、神経代謝障害に関連する疾患の治療、神経代謝障害に関連する疾患の予防、食欲制御、気分制御、止血機能制御、および免疫応答制御のうち少なくとも1つのための組成物であって、以下の式(I)の化合物と薬学的に許容される担体から成る組成物:
- 前記式(I)の化合物が、経口投与、経皮投与、静脈内注射、および皮下注射のうち少なくとも1つによって投与される請求項1に記載の組成物。
- 前記組成物が医薬組成物であり、かつメラトニン合成の増加、メラトニン分泌の促進、神経代謝障害に関連する疾患の治療、および神経代謝障害に関連する疾患の予防のうち少なくとも1つのための組成物である請求項1に記載の組成物。
- 不眠を治療するための組成物である請求項3に記載の組成物。
- 前記組成物が食品組成物であり、かつ睡眠障害改善、ならびに睡眠制御、食欲制御、気分制御、止血機能制御、および免疫応答制御のうち少なくとも1つのための組成物である請求項1に記載の組成物。
- DDC遺伝子発現の増加、AANAT遺伝子発現の増加、およびASMTL遺伝子発現の増加のうち少なくとも1つのための組成物であって、以下の式(I)の化合物と薬学的に許容される担体から成る組成物:
- 前記式(I)の化合物が、経口投与、経皮投与、静脈内注射、および皮下注射のうち少なくとも1つによって投与される請求項6に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762590129P | 2017-11-22 | 2017-11-22 | |
TW107133010 | 2018-09-19 | ||
TW107133010A TWI670059B (zh) | 2017-11-22 | 2018-09-19 | 沒食子兒茶素之應用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020045328A JP2020045328A (ja) | 2020-03-26 |
JP6807423B2 true JP6807423B2 (ja) | 2021-01-06 |
Family
ID=67348104
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019053867A Active JP6807423B2 (ja) | 2017-11-22 | 2019-03-20 | ガロカテキンの使用 |
JP2019053868A Active JP6840178B2 (ja) | 2017-11-22 | 2019-03-20 | ヒドロキシアニゴルホンの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019053868A Active JP6840178B2 (ja) | 2017-11-22 | 2019-03-20 | ヒドロキシアニゴルホンの使用 |
Country Status (4)
Country | Link |
---|---|
US (3) | US10646466B2 (ja) |
JP (2) | JP6807423B2 (ja) |
CN (2) | CN109806257A (ja) |
TW (2) | TWI670059B (ja) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3517274B2 (ja) | 1994-05-20 | 2004-04-12 | 株式会社ナリス化粧品 | 皮膚組成物 |
GB9808796D0 (en) | 1998-04-24 | 1998-06-24 | Rowett Research Services Limit | Antithrombotic agents |
US20070298133A1 (en) * | 2006-06-23 | 2007-12-27 | The Procter & Gamble Company | Compositions and kits comprising a melatonin component and a flavanol component |
WO2009149288A2 (en) | 2008-06-04 | 2009-12-10 | Herbalscience Group Llc | Extracts of cranberry and methods of using thereof |
EA028836B1 (ru) | 2009-08-12 | 2018-01-31 | Мунисекхар Медасани | Натуральный экстракт из цельных плодов банана (musa spp.) |
CN101824021B (zh) * | 2009-10-14 | 2013-01-09 | 南开大学 | 莲藕中儿茶素类小分子的提取方法及其应用 |
WO2018134962A1 (ja) | 2017-01-20 | 2018-07-26 | マルカイコーポレーション株式会社 | 頻尿の改善剤 |
-
2018
- 2018-09-19 TW TW107133010A patent/TWI670059B/zh active
- 2018-09-20 CN CN201811101637.4A patent/CN109806257A/zh active Pending
- 2018-10-08 TW TW107135407A patent/TWI657817B/zh active
- 2018-10-10 CN CN201811176612.0A patent/CN109806248A/zh active Pending
- 2018-11-06 US US16/182,158 patent/US10646466B2/en active Active
- 2018-11-09 US US16/185,429 patent/US10646455B2/en active Active
-
2019
- 2019-03-20 JP JP2019053867A patent/JP6807423B2/ja active Active
- 2019-03-20 JP JP2019053868A patent/JP6840178B2/ja active Active
-
2020
- 2020-01-29 US US16/776,190 patent/US10905674B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP6840178B2 (ja) | 2021-03-10 |
TW201924671A (zh) | 2019-07-01 |
TWI670059B (zh) | 2019-09-01 |
US10646455B2 (en) | 2020-05-12 |
JP2020045328A (ja) | 2020-03-26 |
CN109806257A (zh) | 2019-05-28 |
CN109806248A (zh) | 2019-05-28 |
JP2020059691A (ja) | 2020-04-16 |
TW201924666A (zh) | 2019-07-01 |
US10905674B2 (en) | 2021-02-02 |
US10646466B2 (en) | 2020-05-12 |
TWI657817B (zh) | 2019-05-01 |
US20190151257A1 (en) | 2019-05-23 |
US20190151281A1 (en) | 2019-05-23 |
US20200163907A1 (en) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2946825C (en) | Muscle atrophy inhibitor containing quercetin glycoside | |
KR20090097922A (ko) | 스테로이드 요법에 있어서의 부작용의 개선·억제용 조성물 | |
EP3520788A1 (en) | Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis | |
JP2011241209A (ja) | ガングリオシド又はその誘導体を有効成分とするbdnf産生促進剤並びにそれを含有する医薬品、飲食品及び飼料 | |
JP6807423B2 (ja) | ガロカテキンの使用 | |
US9968585B2 (en) | Prevention or treatment agent for cerebral amyloid beta storage diseases | |
JP2007176804A (ja) | 痩身作用を有する医薬又は健康食品 | |
CN115867270A (zh) | 烟酰胺腺嘌呤二核苷酸(nad)浓度上升剂 | |
WO2000066118A1 (fr) | Compositions pour le traitement de l'infarctus cerebral | |
WO2013176220A1 (ja) | 概日リズム調整 | |
JP4428481B2 (ja) | 神経因性疼痛治療剤 | |
US11766458B2 (en) | Method and a dietary composition on regulation, treatment, and prevention of obesity | |
CN109260235A (zh) | 一种组合物在制备防治便秘药物或保健品中的应用 | |
EP1964558A1 (en) | Pharmaceutical compositions containing intestinal lipase inhibiting substances combined with a chromium dinicotinate o-coordinated complex for use in the treatment and control of obesity and overweight | |
EP3964228A1 (en) | Composition for preventing or treating obesity, comprising phospholipase a2 as active ingredient | |
WO2010098475A1 (ja) | 摂食障害予防及び治療剤 | |
US20230024207A1 (en) | Method and a dietary composition on regulation, treatment, and prevention of obesity | |
JP2009539941A (ja) | Slv308およびl−dopaを含んでなる組み合わせ製剤 | |
WO2008001495A1 (fr) | Agent contre les contraintes psychosociales | |
JP2009084211A (ja) | 神経細胞賦活組成物 | |
JP6706852B2 (ja) | 細胞老化抑制剤 | |
WO2019066010A1 (ja) | 非アルコール性脂肪性肝炎の予防又は治療剤及びその使用 | |
JP2016074617A (ja) | 脂肪蓄積抑制剤 | |
CN108245499A (zh) | 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途 | |
CN112656791A (zh) | 一种治疗枫糖尿病的化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200511 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200831 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201120 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201207 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6807423 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |